Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue

Molecular drugs targeting mutated or rearranged oncogene drivers have become one of the standard recognized treatments in patients with advanced and recurrent non-small cell lung cancer. RET is located in the long arm of human chromosome 10 and encodes a receptor tyrosine kinase protein, and RET fus...

Full description

Bibliographic Details
Main Authors: Shinkichi Takamori, Taichi Matsubara, Naoki Haratake, Gouji Toyokawa, Takatoshi Fujishita, Ryo Toyozawa, Kensaku Ito, Masafumi Yamaguchi, Kenichi Taguchi, Tatsuro Okamoto, Takashi Seto
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
RET
multikinase inhibitor
selective inhibitor
targeted therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.704084/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.704084/full

Similar Items